Moderna (MRNA) Assets Average (2019 - 2026)
Moderna (MRNA) posted quarterly Assets Average of $11.2 billion for Q2 2026, down 9.16% year-over-year from $12.4 billion in Q2 2025, and down 5.78% on a QoQ basis from $11.9 billion in Q1 2026.
Moderna (MRNA) Assets Average (2019 - 2026) Analysis & Trends
Moderna has reported Assets Average for 8 years, with the latest figure at $11.2 billion in Q2 2026.
- Assets Average for Q2 2026 came in at $11.2 billion, down 9.16% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.2 billion (down 9.16% YoY), and the FY2025 annual result was $13.2 billion, down 18.69% from the prior year.
- Assets Average retreated to $11.2 billion in Q2 2026, from $11.9 billion in the prior quarter.
- Over five years, Assets Average peaked at $26.8 billion in Q2 2022 and troughed at $11.2 billion in Q2 2026.
- A 5-year average of $18.3 billion and a median of $16.9 billion in 2024 frame the typical range for Assets Average.
- The widest annual swing landed in 2022, when Assets Average surged 160.99%; it then retreated 29.67% in 2024.
- A 5-year view of Assets Average shows it stood at $26.0 billion in 2022, then slipped by 27.04% to $18.9 billion in 2023, then fell by 20.94% to $15.0 billion in 2024, then dropped by 18.27% to $12.2 billion in 2025, then fell by 8.27% to $11.2 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $11.2 billion in Q2 2026, $11.9 billion in Q1 2026, and $12.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Roivant Sciences | 26.52 Bn | 26.52 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.22 Bn |
| Mar 31, 2026 | 11.91 Bn |
| Dec 31, 2025 | 12.24 Bn |
| Sep 30, 2025 | 12.07 Bn |
| Jun 30, 2025 | 12.36 Bn |
| Mar 31, 2025 | 13.42 Bn |
| Dec 31, 2024 | 14.97 Bn |
| Sep 30, 2024 | 15.74 Bn |
| Jun 30, 2024 | 16.20 Bn |
| Mar 31, 2024 | 17.58 Bn |
| Dec 31, 2023 | 18.94 Bn |
| Sep 30, 2023 | 20.67 Bn |
| Jun 30, 2023 | 23.00 Bn |
| Mar 31, 2023 | 24.99 Bn |
| Dec 31, 2022 | 25.96 Bn |
| Sep 30, 2022 | 26.05 Bn |
| Jun 30, 2022 | 26.83 Bn |
| Mar 31, 2022 | 26.14 Bn |
| Dec 31, 2021 | 22.80 Bn |
| Sep 30, 2021 | 18.54 Bn |